These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. Albershardt TC; Salerni BL; Soderquist RS; Bates DJ; Pletnev AA; Kisselev AF; Eastman A J Biol Chem; 2011 Jul; 286(28):24882-95. PubMed ID: 21628457 [TBL] [Abstract][Full Text] [Related]
4. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663 [TBL] [Abstract][Full Text] [Related]
5. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841 [TBL] [Abstract][Full Text] [Related]
6. MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex. Djajawi TM; Liu L; Gong JN; Huang AS; Luo MJ; Xu Z; Okamoto T; Call MJ; Huang DCS; van Delft MF Cell Death Differ; 2020 Aug; 27(8):2484-2499. PubMed ID: 32094511 [TBL] [Abstract][Full Text] [Related]
7. MARCH5-dependent degradation of MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment. Haschka MD; Karbon G; Soratroi C; O'Neill KL; Luo X; Villunger A Cell Death Differ; 2020 Aug; 27(8):2297-2312. PubMed ID: 32015503 [TBL] [Abstract][Full Text] [Related]
8. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner. Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis. Remy J; Linder B; Weirauch U; Konovalova J; Marschalek R; Aigner A; Kögel D Biochim Biophys Acta Mol Cell Res; 2019 Feb; 1866(2):175-189. PubMed ID: 30389373 [TBL] [Abstract][Full Text] [Related]
10. The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA. Soderquist R; Pletnev AA; Danilov AV; Eastman A Apoptosis; 2014 Jan; 19(1):201-9. PubMed ID: 24072590 [TBL] [Abstract][Full Text] [Related]
12. MARCH5 regulates mitotic apoptosis through MCL1-dependent and independent mechanisms. Wang Y; Poon RYC Cell Death Differ; 2023 Mar; 30(3):753-765. PubMed ID: 36329234 [TBL] [Abstract][Full Text] [Related]
13. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Hauck P; Chao BH; Litz J; Krystal GW Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561 [TBL] [Abstract][Full Text] [Related]
15. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332 [TBL] [Abstract][Full Text] [Related]
16. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477. Mallick DJ; Soderquist RS; Bates D; Eastman A Cell Death Dis; 2019 Feb; 10(3):185. PubMed ID: 30796196 [TBL] [Abstract][Full Text] [Related]
17. Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer. Nakajima W; Hicks MA; Tanaka N; Krystal GW; Harada H Cell Death Dis; 2014 Feb; 5(2):e1052. PubMed ID: 24525728 [TBL] [Abstract][Full Text] [Related]
18. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671 [TBL] [Abstract][Full Text] [Related]
19. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235 [TBL] [Abstract][Full Text] [Related]
20. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]